BOSTON MEDICAL CENTER
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $39.9M
- Transactions
- 3,256
- Companies
- 40
- Average per transaction
- $12,246
Who reported the payments
| Pfizer | $12,391,222 |
| Merck | $3,840,126 |
| Gilead | $2,296,707 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,887,033 |
| E.r. Squibb & Sons, L.L.C. | $1,808,932 |
| Janssen Research & Development, LLC | $1,584,107 |
| Vertex | $1,421,861 |
| Genentech, Inc. | $1,163,396 |
| AstraZeneca | $1,088,276 |
| Novartis | $998,242 |
| AbbVie | $811,588 |
| Eli Lilly | $657,656 |
| G1 Therapeutics, Inc. | $536,620 |
| Indivior Inc. | $504,939 |
| Zevra Therapeutics Inc | $450,670 |
| Abbott | $432,742 |
| KARL Storz Endoscopy-america | $421,462 |
| Regeneron | $407,022 |
| Hoffmann-la Roche Limited | $307,542 |
| C. R. Bard, Inc. & Subsidiaries | $301,106 |
| Karyopharm Therapeutics Inc. | $299,793 |
| Amgen | $279,838 |
| Novo Nordisk AS | $276,801 |
| Deciphera Pharmaceuticals Inc. | $258,360 |
| Coloplast | $245,000 |
| Biogen | $234,221 |
| Madrigal Pharmaceuticals | $217,071 |
| Theratechnologies Inc. | $204,983 |
| Lexicon Pharmaceuticals, Inc. | $191,114 |
| Alnylam Pharmaceuticals Inc. | $167,000 |
| Tandem Diabetes Care, Inc. | $142,035 |
| Bristol Myers Squibb | $137,682 |
| Philips North America LLC | $137,393 |
| Convatec Inc. | $137,352 |
| Otsuka Pharmaceutical Co., Ltd. | $134,493 |
| Laminate Medical Technologies Inc. | $133,579 |
| Acera Surgical, Inc. | $126,266 |
| Sequel Med Tech, LLC | $125,609 |
| Intercept Pharmaceuticals, Inc. | $123,259 |
| Global Blood Therapeutics, Inc. | $120,291 |